Healio

FibroScan after endoscopy found undiagnosed NAFLD, NASH

PHILADELPHIA — FibroScan screening for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis could significantly improve patient diagnosis and care, as data presented at the American ...
KUTV

Check Your Health: A simple non-invasive test can tell you if you have a fatty liver

KUTV — Fatty liver disease is a chronic liver disease and is a rapidly growing problem here in Utah. It’s important to catch this disease early with a simple, non-invasive test and then make the ...
The Herald-Dispatch

Marshall Health offering non-invasive testing for liver disease using latest FibroScan® technology

The Tri-State’s TRUSTED news source. Click here to stay informed and subscribe to Herald-Dispatch. Click #isupportlocal for more information on supporting our local journalists. SCOTT DEPOT, W.Va. — ...
Business Wire

Echosens and ChronWell Announce Exclusive Strategic Partnership Between FibroScan and LIVErHEALTHY to Improve Patient Outcomes and Cost Savings

WALTHAM, Mass. & FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Echosens North America, a high-technology company offering the FibroScan ® portfolio of solutions, and ChronWell, a digital health and ...
The Grand Junction Daily Sentinel

FibroScan device simplifies local liver scans

Just a few years ago, Grand Junction gastroenterologist Dr. William Shields was administering a lot of biopsies to diagnose the level of scarring in a patient's liver. The process involves a needle ...
Business Wire

Echosens Presents Research at 2021 AASLD Liver Meeting: Early Detection and Monitoring with FibroScan Mitigates Risk of Patients Developing Fibrosis/Cirrhosis

PARIS & WALTHAM, Mass.--(BUSINESS WIRE)--Echosens, a high-technology company offering the FibroScan ® family of products, is pleased to announce its strong presence at the upcoming American ...
Healio

Q&A: FAST score, other noninvasive tests help identify, stratify at-risk MASH patients

Please provide your email address to receive an email when new articles are posted on . Researchers recommended the FibroScan-AST score to target those at risk for MASH. The score should be used with ...
Morningstar

FDA Accepts Letter of Intent to Qualify LSM by VCTE (FibroScan®) as First Non-Invasive Surrogate Endpoint in MASH Clinical Trials

This milestone opens a path for FibroScan® to ultimately replace liver biopsy for patient enrollment and treatment response assessment in MASH drug development WESTBOROUGH, Mass., Sept. 8, 2025 ...
manilatimes

FDA Accepts Letter of Intent to Qualify LSM by VCTE (FibroScan®) as First Non-Invasive Surrogate Endpoint in MASH Clinical Trials

This milestone opens a path for FibroScan® to ultimately replace liver biopsy for patient enrollment and treatment response assessment in MASH drug development This is the first time the FDA is ...